Abortion pill trials are testing potentially lifesaving drugs in new pill regimens for aborting preborn children. In their latest scheme to expand access to abortion, Gynuity Health Projects (GHP) is substituting the drug Letrozole in place of the approved abortion drug Mifeprex (mifepristone) for abortions. Separately, University of Utah is the trial sponsor for experimenting with the generic version of Lipitor as a replacement for Mifeprex. Both drugs would be paired with misoprostol and tested at Planned Parenthood Salt Lake Health Center in Salt Lake City, Utah.
In 2000, the Food and Drug Administration (FDA) approved Mifeprex in a regimen with the ulcer medication misoprostol for abortion. Shortly after the approval, women began to die and the drug was eventually placed under a safety system called the Risk Evaluation and Mitigation System (REMS), where the FDA could monitor it more closely. The REMS has been weakened over past years and was recently changed under the Biden FDA to allow the regimen’s permanent distribution by mail. The move followed a litany of clinical trials rolled out by abortion insiders, many of whom had close ties or monetary benefits from the drug manufacturers, Danco Laboratories and GenBioPro (generic).
Letrozole and misoprostol for abortion
Now a new study, sponsored by Gynuity Health Projects (GHP) is looking at, “Letrozole and Misoprostol for Termination of Pregnancy up to 63 Days’ Gestation” to determine “if a user-friendly medical abortion regimen using letrozole and misoprostol is safe and acceptable.”
Letrozole is the active ingredient and generic of the drug FEMARA, approved in 1997, and according to the latest label (2018) FEMARA is contraindicated for pregnancy. Drugs.com warns, “Femara can harm an unborn baby or cause birth defects. Do not use if you are pregnant.” Femara or Letrozole is currently being used to treat breast cancer, and according to Drugs.com, it “lowers estrogen levels in postmenopausal women, which may slow the growth of certain types of breast tumors that need estrogen to grow in the body.”
The clinical trial was implemented under the leadership of Gynuity staffers Tara Shochet and Beverly Winikoff as well as University of Utah’s David Turok, MD. It was set to begin recruiting 40 participants (18-50 years of age) in December of 2021 and was expected to be finished by March 2022, but to date the trial still shows it is “recruiting.” Participants were to receive abortions at Planned Parenthood Salt Lake Health Center in Salt Lake City by taking a regimen of “30 mg letrozole on day 1 followed by 800 mcg misoprostol on day 3.”
Gynuity is funded heavily by those who also financially seeded the abortion pill manufacturer, and the organization is under the direction of Winikoff, who took part in the original clinical trials of RU-486 (as the abortion pill was known in the 1990s) when she worked for the eugenics-founded Population Council. Winikoff has served on the board of the National Abortion Federation (NAF), which was at one time directly funded by Danco, as well as the Buffett and Packard Foundations. Winikoff has credited the 9/11 terrorist attacks with saving the abortion pill by drowning out the news of a woman’s death from the abortion pill.
Principal Investigator David Turok, M.D., is an Associate Professor in the University of Utah Department of Obstetrics and Gynecology, and is board certified in Obstetrics and Gynecology and Family Practice. He also commits abortions and has been listed as is the Director of Surgical Services at Planned Parenthood Associates of Utah in past reports.
Letrozole, like misoprostol and unlike Mifeprex, is not restricted by the FDA under the REMS, which may explain why the abortion industry is testing the drug. In 2017, a systematic review to “evaluate the efficacy of pretreatment with letrozole prior to either a first- or second-trimester medical termination of pregnancy” was published in Journal Contraception. In 2013, a pilot study on the “combined use of letrozole, mifepristone and misoprostol in termination of first trimester pregnancy up to 9 weeks gestation” was published in a European journal while another study was published in the Green Journal in 2011.
Atorvastatin (Lipitor) and misoprostol for abortion
A separate drug trial using Atorvastatin as “a Potential Adjunct to Misoprostol for Termination of Pregnancy” is being sponsored by the University of Utah under the direction of the previously mentioned Dr. Turok. This trial was published in April of 2022 and is currently recruiting thirty participants (18-50 years-old) at the same Planned Parenthood Association of Utah location. This study is expected to be conducted through July 2022.
“Finding another medication that replaces mifepristone would benefit both those who need abortions and providers around the world. Atorvastatin might be one drug that could do this. It is a statin that is commercially available in many countries,” the study states.
According to Drugs.com, Atorvastatin is the generic for the drug Lipitor, which is an inhibitor of “statins” used to lower cholesterol. The drug is also not restricted by the FDA’s REMS.
Whatever the outcome of these trials, the profitable abortion industry has no plans to relinquish its chemical experiments on women. It is now estimated that using the currently approved abortion pill regimen, 465,000 babies are killed annually, and as of June of 2021, the abortion pill has tragically ended the lives of nearly 5 million preborn babies since its approval in 2000. This likely grosses the industry an estimated $300 million each year.
“Like” Live Action News on Facebook for more pro-life news and commentary!